AEMD

NASDAQ

Aethlon Medical Inc.

SectorHealth CareIndustryMedical/Dental Instruments

News25/Ratings2

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.

News · 26 weeks43+50%

2025-10-262026-04-19

Mix2690d

Other9(35%)
SEC Filings7(27%)
Insider7(27%)
Earnings2(8%)
Leadership1(4%)

Latest news

25 items

2dINSIDER
SEC Form 4 filed by Gikakis Nicolas
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
2dINSIDER
SEC Form 4 filed by Broenniman Edward G
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
2dINSIDER
SEC Form 4 filed by Rossetti Angela
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
2dINSIDER
SEC Form 4 filed by Shah Chetan
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
22dINSIDER
SEC Form 4 filed by Shah Chetan
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
22dINSIDER
SEC Form 4 filed by Gikakis Nicolas
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
22dINSIDER
SEC Form 4 filed by Broenniman Edward G
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
22dPR
Presenting on Emerging Growth Conference 91 Day 2 on April 2; Register to live stream
MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 – Presenting TodayWednesday, April 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you a
23dPR
Presenting on Emerging Growth Conference 91 Day 1 on April 1; Register to live stream
MIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - WednesdayApril 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to
30dPR
Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review
SAN DIEGO, March 24, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review of the second cohort participant data and recommended advancing to the third and final cohort. They also stated that "no safety concerns were noted with Hemopurifier device/procedure". The trial, titled "Safety, Feasibility, and Dose-Finding Study of Aethlon Hemopurifier in Patients with Solid Tumors
37dSEC
SEC Form 8-K filed by Aethlon Medical Inc.
8-K - AETHLON MEDICAL INC (0000882291) (Filer)
41dPR
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry. REGISTER AND VIEW PRESENTATIONS HERE The presentations will be available 24/7 for 90 days. Investors,
42dPR
Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities
SAN DIEGO, March 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is evaluating a range of strategic opportunities and has engaged Maxim Group LLC ("Maxim") to act as the Company's exclusive financial advisor in connection with this process. The Company engaged Maxim following preliminary inbound interest regarding potential strategic opportunities. Maxim will assist the Company in reviewing a range of potential transactions, including partnerships, mergers, acquisitions or other opportunities involving the Co
44dPR
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place March 11–12, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here "We are delighted to highlight today's innovators from the Life Science
48dPR
Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th
SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that Jim Frakes, CEO and CFO, will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on March 12th, 2026. DATE: Thursday, March 12thTIME: 1:00 – 1:30 pm ET REGISTER HERE Available for 1x1 meetings: March 12th. Schedule 1x1 Meetings here. The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportun
57dPR
Presenting on Emerging Growth Conference 90 Day 2 on February 26; Register to live stream
MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 90th Emerging Growth Conference on February 25 & 26, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - February 25, 2026 – Agenda for Today: 8:45Virtual Lobby opens.Register for the Conference. If you already regi
58dPR
Presenting on Emerging Growth Conference 90 Day 1 on February 25; Register to live stream
MIAMI, Feb. 24, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 90th Emerging Growth Conference on February 25 & 26, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - WednesdayFebruary 25, 2026 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go
59dSEC
Aethlon Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
8-K - AETHLON MEDICAL INC (0000882291) (Filer)
59dPR
Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026
Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and CFO, Jim Frakes in
70dSEC
SEC Form 10-Q filed by Aethlon Medical Inc.
10-Q - AETHLON MEDICAL INC (0000882291) (Filer)
70dSEC
Aethlon Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - AETHLON MEDICAL INC (0000882291) (Filer)
70dPR
Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update
Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments. Key Highlights Maintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved. Clinical Progress: Cohort 2 of the Australian oncology tr
78dPR
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026
SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2025, at 4:15 p.m. ET on Thursday, February 12, 2026. Management will host a conference call on Thursday, February 12, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10206585/1034
86dSEC
SEC Form DEFA14A filed by Aethlon Medical Inc.
DEFA14A - AETHLON MEDICAL INC (0000882291) (Filer)
86dSEC
SEC Form 424B3 filed by Aethlon Medical Inc.
424B3 - AETHLON MEDICAL INC (0000882291) (Filer)